These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 35456161)
1. Dysthyroid Optic Neuropathy: Treatment with Additional Intravenous Methylprednisolone Pulses after the Basic Schedule Is Associated with Stabilization or Further Improvement of Clinical Outcome. Pelewicz M; Rymuza J; Pelewicz K; Miśkiewicz P J Clin Med; 2022 Apr; 11(8):. PubMed ID: 35456161 [TBL] [Abstract][Full Text] [Related]
2. A single-center analysis of visual outcomes and associated factors after intravenous methylprednisolone treatment for dysthyroid optic neuropathy. Kemchoknatee P; Tangon D; Srisombut T BMC Ophthalmol; 2023 Jan; 23(1):32. PubMed ID: 36690985 [TBL] [Abstract][Full Text] [Related]
3. Complete recovery of visual acuity as the main goal of treatment in patients with dysthyroid optic neuropathy. Miśkiewicz P; Rutkowska B; Jabłońska A; Krzeski A; Trautsolt-Jeziorska K; Kęcik D; Milczarek-Banach J; Pirko-Kotela K; Samsel A; Bednarczuk T Endokrynol Pol; 2016; 67(2):166-73. PubMed ID: 26884288 [TBL] [Abstract][Full Text] [Related]
7. Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients with Graves' Orbitopathy. Miśkiewicz P; Jankowska A; Brodzińska K; Milczarek-Banach J; Ambroziak U Int J Endocrinol; 2018; 2018():1978590. PubMed ID: 30420883 [TBL] [Abstract][Full Text] [Related]
8. Dysthyroid optic neuropathy: a case series at a tertiary ophthalmic referral centre. Chung IY; Hardy TG; Khong JJ Eye (Lond); 2024 Apr; 38(6):1168-1172. PubMed ID: 38081935 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy. Currò N; Covelli D; Vannucchi G; Campi I; Pirola G; Simonetta S; Dazzi D; Guastella C; Pignataro L; Beck-Peccoz P; Ratiglia R; Salvi M Thyroid; 2014 May; 24(5):897-905. PubMed ID: 24417307 [TBL] [Abstract][Full Text] [Related]
10. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids]. Cirić J; Zarković M; Stojanović M; Pepenezić Z; Randjelović G; Gligorović M; Trbojević B; Drezgić M; Nesović M Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418 [TBL] [Abstract][Full Text] [Related]
11. Clinical and Visual Outcomes of Dysthyroid Optic Neuropathy After Surgical Orbital Decompression. Currò N; Guastella C; Pirola G; Calonghi B; Bottari de Castello A; Fazio MC; di Benedetto S; Minorini V; Daga M; Contarino A; Muller I; Arosio M; Viola F; Pignataro L; Salvi M Thyroid; 2023 Jun; 33(6):743-751. PubMed ID: 37140534 [No Abstract] [Full Text] [Related]
12. Glucocorticoid-induced adrenal insufficiency after therapy with intravenous methylprednisolone in patients with moderate-to-severe and active Graves' orbitopathy: assessment with a low-dose corticotropin test. Pelewicz K; Miśkiewicz P J Endocrinol Invest; 2024 Aug; 47(8):1987-1994. PubMed ID: 38310626 [TBL] [Abstract][Full Text] [Related]
13. Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: A multicenter study. Sears CM; Wang Y; Bailey LA; Turbin R; Subramanian PS; Douglas R; Cockerham K; Kossler AL Am J Ophthalmol Case Rep; 2021 Sep; 23():101111. PubMed ID: 34113737 [TBL] [Abstract][Full Text] [Related]
14. Acute dysthyroid optic neuropathy exacerbated by orbital radiotherapy. Hersh D; Kinnar M Orbit; 2014 Oct; 33(5):385-7. PubMed ID: 24841498 [TBL] [Abstract][Full Text] [Related]
15. [Therapeutic outcomes and influence factors of maximal orbital decompression in the treatment of severe dysthyroid optic neuropathy]. Wang Y; Li YY; Yang N; Ma R; Xiao LH Zhonghua Yan Ke Za Zhi; 2017 Jun; 53(6):416-423. PubMed ID: 28606262 [TBL] [Abstract][Full Text] [Related]
16. Macular blood flow changes in dysthyroid optic neuropathy after high-dose intravenous pulse methylprednisolone (IVMP). Fan SX; Liang JQ; Wang J; Zhou C; Zhou SY; Wang M; Zeng P Photodiagnosis Photodyn Ther; 2024 Feb; 45():103935. PubMed ID: 38104706 [TBL] [Abstract][Full Text] [Related]
17. Blood Pressure Profile and N-Terminal-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy. Miskiewicz P; Milczarek-Banach J; Bednarczuk T; Opolski G; Glowczynska R Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30261581 [TBL] [Abstract][Full Text] [Related]
18. Insights into Current Management Strategies for Dysthyroid Optic Neuropathy: A Review. Tagami M; Honda S; Azumi A Clin Ophthalmol; 2022; 16():841-850. PubMed ID: 35330749 [TBL] [Abstract][Full Text] [Related]
19. Therapy With Intravenous Methylprednisolone Pulses Is Associated With Loss of Bone Microarchitecture in Trabecular Bone Score -Assessment Among Patients With Moderate-to-Severe Graves' Orbitopathy: A Pilot Study. Rymuza J; Pelewicz K; Przedlacki J; Miśkiewicz P Front Endocrinol (Lausanne); 2022; 13():893600. PubMed ID: 35909547 [TBL] [Abstract][Full Text] [Related]
20. Management of patients with dysthyroid optic neuropathy treated with intravenous corticosteroids and/or orbital decompression surgery. Rezar-Dreindl S; Papp A; Baumann A; Neumayer T; Eibenberger K; Stifter E; Schmidt-Erfurth U Graefes Arch Clin Exp Ophthalmol; 2022 Nov; 260(11):3683-3691. PubMed ID: 35731314 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]